Fabry disease is a multisystem, X-linked, lysosomal storage disorder caused by a mutation in the GLA gene on chromosome Xq22 resulting in alpha-galactosidase A enzyme (a-Gal A) deficiency. Neurological manifestations other than cerebrovascular accidents include small fibre neuropathy and dysautonomic disorders, which may be the presenting clinical features in a proportion of patients. An atypical disease onset may be misdiagnosed until the emergence of a more typical clinical picture, characterized by chronic renal and cardiac failure. Thus, neurologists should consider Fabry disease in differential diagnosis and provide an appropriate diagnostic work up. This review focuses on central and peripheral nervous system involving available diagnostic tools and diagnostic work up in Fabry disease. It also covers the most recent evidence regarding enzyme replacement therapy.

Neurological features of Fabry disease: clinical, pathophysiological aspects and therapy / A. Bersano, S. Lanfranconi, C. Valcarenghi, N. Bresolin, G. Micieli, P. Baron. - In: ACTA NEUROLOGICA SCANDINAVICA. - ISSN 0001-6314. - 126:2(2012 Aug), pp. 77-97.

Neurological features of Fabry disease: clinical, pathophysiological aspects and therapy

N. Bresolin;
2012

Abstract

Fabry disease is a multisystem, X-linked, lysosomal storage disorder caused by a mutation in the GLA gene on chromosome Xq22 resulting in alpha-galactosidase A enzyme (a-Gal A) deficiency. Neurological manifestations other than cerebrovascular accidents include small fibre neuropathy and dysautonomic disorders, which may be the presenting clinical features in a proportion of patients. An atypical disease onset may be misdiagnosed until the emergence of a more typical clinical picture, characterized by chronic renal and cardiac failure. Thus, neurologists should consider Fabry disease in differential diagnosis and provide an appropriate diagnostic work up. This review focuses on central and peripheral nervous system involving available diagnostic tools and diagnostic work up in Fabry disease. It also covers the most recent evidence regarding enzyme replacement therapy.
No
English
Fabry disease; neurological aspects; stroke; neuropathy; enzyme replacement therapy
Settore MED/26 - Neurologia
Articolo
Esperti anonimi
Pubblicazione scientifica
ago-2012
19-mar-2012
126
2
77
97
21
Pubblicato
Periodico con rilevanza internazionale
Aderisco
info:eu-repo/semantics/article
Neurological features of Fabry disease: clinical, pathophysiological aspects and therapy / A. Bersano, S. Lanfranconi, C. Valcarenghi, N. Bresolin, G. Micieli, P. Baron. - In: ACTA NEUROLOGICA SCANDINAVICA. - ISSN 0001-6314. - 126:2(2012 Aug), pp. 77-97.
reserved
Prodotti della ricerca::01 - Articolo su periodico
6
262
Article (author)
si
A. Bersano, S. Lanfranconi, C. Valcarenghi, N. Bresolin, G. Micieli, P. Baron
File in questo prodotto:
File Dimensione Formato  
Bersano_et_al-2012-Acta_Neurologica_Scandinavica.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 445.24 kB
Formato Adobe PDF
445.24 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/299028
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 28
  • ???jsp.display-item.citation.isi??? 24
social impact